


RNASEH2B loss and PARP inhibition in advanced prostate cancer

Juliet Carmichael, ... , Adam Sharp, Johann de Bono

J Clin Invest. 2024. <https://doi.org/10.1172/JCI178278>.

Clinical Medicine In-Press Preview Oncology

Graphical abstract



Find the latest version:

<https://jci.me/178278/pdf>



RNASEH2B loss and PARP inhibition in advanced prostate cancer

Juliet Carmichael^{1,2*}, Ines Figueiredo^{1*}, Bora Gurel^{1*}, Nick Beijer^{1,2*}, Wei Yuan¹, Jan Rekowski¹, George Seed¹, Suzanne Carreira¹, Claudia Bertan¹, Maria de Los Dolores Fenor de La Maza^{1,2}, Khobe Chandran^{1,2}, Antje Neeb¹, Jon Welti¹, Lewis Gallagher¹, Denisa Bogdan¹, Mateus Crespo¹, Ruth Riisnaes¹, Ana Ferreira¹, Susana Miranda¹, Jinqiu Lu³, Michael M. Shen³, Emma Hall¹, Nuria Porta¹, Daniel Westaby^{1,2}, Christina Guo^{1,2}, Rafael Grochot^{1,2}, Christopher J. Lord¹, Joaquin Mateo^{1,2}, Adam Sharp^{1,2}, Johann de Bono^{1,2}

1. The Institute of Cancer Research, London, UK
2. The Royal Marsden NHS Foundation Trust, London, UK
3. Departments of Medicine, Genetics & Development, Urology, and Systems Biology, Columbia University Irving Medical Center, New York, NY, USA

*J.C., I.F, B.G and N.B. contributed equally to this paper

To whom correspondence should be addressed:

Johann de Bono

The Institute of Cancer Research

15 Cotswold Road

London SM2 5NG

Johann.de-bono@icr.ac.uk

+44 (0) 208 722 4028

Abstract

BACKGROUND

Clinical trials have suggested antitumor activity from PARP inhibition beyond homologous recombination deficiency (HRD). *RNASEH2B* loss is unrelated to HRD and preclinically sensitizes to PARP inhibition. The current study reports on *RNASEH2B* protein loss in advanced prostate cancer and its association with *RB1* protein loss, clinical outcome and clonal dynamics during treatment with PARP inhibition in a prospective clinical trial.

METHODS

Whole tumor biopsies from multiple cohorts of patients with advanced prostate cancer were interrogated using whole-exome sequencing (WES), RNA sequencing (bulk and single nucleus) and immunohistochemistry (IHC) for *RNASEH2B* and *RB1*. Biopsies from patients treated with olaparib in the TOPARP-A and TOPARP-B clinical trials were used to evaluate *RNASEH2B* clonal selection during olaparib treatment.

RESULTS

Shallow co-deletion of *RNASEH2B* and adjacent *RB1*, co-located at chromosome 13q14, was common, deep co-deletion infrequent, and gene loss associated with lower mRNA expression. In castration-resistant PC (CRPC) biopsies, *RNASEH2B* and *RB1* mRNA expression correlated, but single nucleus RNA sequencing indicated discordant loss of expression. IHC studies showed that loss of the two proteins often occurred independently, arguably due to stochastic second allele loss. Pre- and post-treatment metastatic CRPC (mCRPC) biopsy studies from *BRCA1/2* wildtype tumors, treated on the TOPARP phase II trial, indicated that olaparib eradicates *RNASEH2B*-loss tumor subclones.

CONCLUSION

PARP inhibition may benefit men suffering from mCRPC by eradicating tumor subclones with *RNASEH2B* loss.

TRIAL REGISTRATION

Clinicaltrials.gov NCT01682772

RNASEH2B in advanced prostate cancer

FUNDING

AstraZeneca; Cancer Research UK; Medical Research Council; Cancer Research UK; Prostate Cancer UK; Movember Foundation; Prostate Cancer Foundation.

Introduction

Prostate cancer is the second most common male malignancy worldwide, with over 1.4 million cases and 375,000 deaths per year (1). Progression to metastatic castration-resistant prostate cancer (mCRPC) after androgen deprivation therapy (ADT) is invariably fatal with a poor median overall survival of 2-3 years. Intra-patient and inter-patient genomic heterogeneity are incontrovertible features of mCRPC, with 20-30% of tumors harboring genomic aberrations related to DNA damage response (DDR), including *BRCA1/2* and *ATM* (2). DDR aberrations can sensitize to synthetic lethal therapies including poly (ADP-ribose)-polymerase inhibitors (PARPi) (3–5), with the PARPi olaparib transforming clinical practice by improving overall survival (OS) from mCRPC in patients with bi-allelic loss of *BRCA2* or *ATM* (6). Pronounced responses are mainly observed in the *BRCA2*-altered population, especially those with *BRCA2* homozygous deletion (7), but mixed responses are common in other molecular subgroups (8). Recent data combining androgen receptor signaling agents (ARSI) with PARPi for patients in molecularly unselected mCRPC suggest that PARPi may have broader antitumor activity beyond DDR-related gene alterations (9, 10). There remains an urgent need to validate predictive biomarkers identifying tumors sensitive to PARPi beyond *BRCA* gene alterations. Multiple preclinical screens have identified loss of function of RNASEH2B as being synthetic lethal with PARPi (11–13).

RNASEH2 is a heterotrimeric complex of 3 sub-units (A-C), all key to its ability to remove misincorporated ribonucleotides from DNA by ribonucleotide excision repair (RER) (14). These lesions commonly arise during normal cellular processes including transcription (15), DNA replication (16), telomere elongation (17) and non-homologous end-joining (NHEJ) (18). Loss of RNASEH2 leads to an accumulation of misincorporated ribonucleotides and R loops in DNA, triggering DNA strand breaks (19), p53-mediated cell cycle arrest, and induction of DDR (20). Synthetic lethality between RNASEH2 gene loss and PARPi was identified using CRISPR screens (11, 12), with RNASEH2B loss sensitizing cells to a similar level as *BRCA2* loss to PARPi *in vitro* (13). Mechanistically, the absence of RNASEH2 permits alternative processing of ribonucleotide excision by topoisomerase 1, generating lethal PARP-trapping lesions that interfere with normal DNA metabolism by generating double strand DNA breaks

(11). Although loss of RNASEH2 function may occur in mCRPC, this remains inadequately investigated (11).

RNASEH2B is located on chromosome 13q. Large segments of chromosome 13q, including the *RB1* tumor suppressor, are commonly deleted in mCRPC with this associating with poorer prognosis (21). *RB1* loss in prostate cancer is typically sub-clonal and can be detected at diagnosis before treatment but increases at mCRPC with subclonal *RB1* loss in 56% of mCRPC biopsies by fluorescence in-situ hybridization (FISH) in our previously reported studies (22). *RNASEH2B* is adjacent to *RB1* (within 2.5Mb on 13q14.3), with whole biopsy data indicating that the two genes may be co-deleted. Studies suggest that *RB1* protein co-loss with *RNASEH2B* loss can decrease PARPi sensitivity (13), so studying *RNASEH2B* also needs to consider *RB1* co-loss. We hypothesized that sub-clonal *RNASEH2B* protein loss emerges at mCRPC due to treatment selective pressure resulting in *RB1* loss. The current study characterizes *RNASEH2B* protein loss in mCRPC, its association with *RB1* protein loss, its impact on clinical outcomes, and its relevance to treatment with PARPi in a prospective clinical trial.

Results

Chromosome 13 shallow deletions encompassing *RB1* and *RNASEH2B* are common in mCRPC and decrease *RB1* and *RNASEH2B* mRNA transcripts.

RNASEH2B and *RB1* are adjacently located on chromosome 13q, along with *BRCA2* (**Figure 1A**). To investigate *RNASEH2B* and *RB1* genomic loss, chromosome 13 deletions were evaluated in circulating tumor DNA (ctDNA) low-pass whole genome sequencing (lpWGS) from mCRPC patients before treatment with taxanes (n=267), demonstrating that shallow deletions encompassing both *RB1* and *RNASEH2B* are common (present in 52% of the samples), and sometimes involve *BRCA2*, with deep deletions occurring infrequently (2% of the samples, **Figure 1B**). As ctDNA copy number alteration (CNA) analyses can be influenced by low tumor fraction, whole-exome sequencing (WES) of whole mCRPC tumor biopsies (n=93) was also interrogated and demonstrated a similar pattern of *RNASEH2B* and *RB1* deletion, with shallow deletion occurring in 55% of samples and deep deletion in 18% of samples (**Figure 1B**). *RNASEH2B* and *RB1* mRNA expression were correlated in two separate CRPC cohorts (SU2C/PCF cohort, $r=0.35$, $p=7 \times 10^{-6}$; RMH cohort, $r=0.6$, $p=3 \times 10^{-10}$; **Figure 1C**); *RNASEH2B* and *RB1* mRNA expression decreased with increasing copy number loss (**Figure 1D**). Single nucleus RNAseq (snRNAseq) studies from six mCRPC patients (n=45,599 single epithelial nuclei) suggested that many nuclei had discordant loss of *RNASEH2B* and *RB1* mRNA (**Figure 1E**). Overall, these data suggested frequent shallow genomic co-loss of *RNASEH2B* and *RB1* occur in mCRPC. Subsequently, the question was raised how these results translated at a protein level.

Validation of a *RNASEH2B* IHC antibody

To be able to evaluate *RNASEH2B* expression at a protein level, a *RNASEH2B* antibody was validated for immunohistochemistry (IHC) utilizing targeted *RNASEH2B* siRNA on both Western blot and cell line pellet IHC. Western blotting confirmed a single band corresponding with *RNASEH2B* expression in HeLa cell lysates treated with non-targeting control siRNA, which was reduced in lysates from HeLa cells treated with *RNASEH2B*-targeting siRNA (**Figure 2A**). Specificity was further confirmed by IHC of HeLa cell pellets treated with *RNASEH2B*-targeting siRNA, non-targeting control siRNA, and HeLa *RNASEH2B* CRISPR-knockouts (**Figure 2B**).

Automated colorimetric digital (HALO™) and visual analyses of RNASEH2B IHC data were correlated (**Figures 2C-E**). HALO™ data were therefore utilized for analyses (one sample was excluded due to unsatisfactory segmentation). Expression of RNASEH2B was predominantly nuclear, consistent with its known mechanism of action; nuclear H score alone was therefore used for IHC analyses. Both homogenous and heterogeneous RNASEH2B protein loss was identified in mCRPC biopsies. Image analyses revealed no detectable morphological difference between RNASEH2B positive and negative cells, with these being dispersed throughout mCRPC biopsy samples (**Figure 2F**). Overall, these data indicated that we had generated arguably the first validated RNASEH2B IHC antibody and confirmed RNASEH2B protein loss in prostate cancer biopsies.

Nuclear RNASEH2B protein loss is heterogeneous and decreases at mCRPC

RNASEH2B expression was evaluated by IHC in 124 CRPC biopsies from patients treated for CRPC at RMH in 2 different cohorts (cohort details in **Supplementary Figure S1**). Biopsies were taken from various metastatic sites, most commonly lymph nodes and bone marrow (**Supplementary Table S1**). Patients were generally pre-treated with both an androgen receptor signaling agent (ARSI) and taxane chemotherapy. Most patients had prostatic adenocarcinoma, whilst few (4/124, 3%) had neuroendocrine prostate cancer (NEPC). Marked intra-tumor and inter-tumor heterogeneity in RNASEH2B expression were observed (**Figure 3A**). Most mCRPC biopsies revealed some tumor cell RNASEH2B IHC loss with 54/124 (44%) samples having loss in $\geq 50\%$ of tumor cells, and 25/124 (20%) in $\geq 75\%$ of tumor cells. Some mCRPC biopsies (11/124, 8.8%) had no RNASEH2B IHC staining. Negative RNASEH2B staining was consistent despite increasing concentrations of the primary RNASEH2B antibody (**Supplementary Figure S2A**). Overall, RNASEH2B IHC expression was lower in bone mCRPC biopsies, although loss was also observed in non-bone marrow samples (**Figure 3B, C**). Therefore, bone decalcification protocols necessary for bone biopsy histopathology studies were tested on xenograft tissues to evaluate artefactual loss of staining (**Supplementary Figures S2B, C**). The EDTA decalcifying agent did impact RNASEH2B staining and may have decreased RNASEH2B expression in bone biopsies, but RNASEH2B nuclear staining was usually still detectable despite this. In the four bone samples with $>90\%$ RNASEH2B-

negative cells, stromal expression was observed (**Supplementary Figure S2D**), suggesting that loss of RNASEH2B was not entirely artefactual in these samples. Stromal protein staining may, at least in part, explain why mCRPC IHC staining quantitation did not correlate well with RNA expression data from a whole biopsy; this is denoted by four exemplar cases with complete loss of RNASEH2B on IHC (highlighted in red) that showed moderate-high levels of RNA expression in RNAseq data (**Supplementary Figure S3A**). RNAish for RNASEH2B confirmed this transcript's more frequent loss in bone biopsies (**Supplementary Figure S3B**), with this correlating well with IHC (**Supplementary Figures S3C**), although it cannot be excluded that RNAish is impacted by decalcification as well.

RNASEH2B expression was also evaluated by IHC in matched, same-patient, HSPC and CRPC biopsies in 72 of the 125 (58%) patients where the HSPC sample was also available. A substantial number of HSPC samples failed quality control assessment (n=37) due to weaker internal controls, and one sample did not have adequate tumor percentage. The number of RNASEH2B-negative cells appeared lower at CRPC (**Figure 3D**), but this analysis could be biased given the generally weaker internal controls in all HSPC samples, suggesting poor protein preservation. Exemplar micrographs of various RNASEH2B IHC expression from HSPC to CRPC are presented in **Figure 3E**. Overall, these data indicated that loss of nuclear RNASEH2B expression is common in CRPC and HSPC but is usually heterogeneous.

RNASEH2B and RB1 proteins are differentially expressed

As sensitivity to PARPi in RNASEH2B-lost prostate cancer may be overridden by RB1 loss (13), RNASEH2B and RB1 protein co-loss was investigated. An RB1 antibody (23) was validated. A single band corresponding to RB1 was observed in 22Rv1 cells, with marked reduction in RB1 detection in cells treated with RB1-targeted siRNA (**Supplementary Figure S4A**). This specificity was confirmed using IHC on 22Rv1 cell pellets treated with RB1 targeting or non-targeting control siRNA, and cells from the RB1 negative triple negative breast cancer (TNBC) cell line MDA-MB-468 (24) (**Supplementary Figure S4B**). Some background staining was observed, and this was accounted for in the HALO™ algorithm. As with RNASEH2B IHC, visual and digital (HALO) analyses correlated well (**Supplementary Figure 4C-E**) and were

utilized for the analyses. RB1 IHC was then performed on 93/125 (74%) of the CRPC biopsies with sufficient tissue. Surprisingly, RB1 protein loss was less frequent than RNASEH2B protein loss; 5/93 (5.4%) mCRPC biopsies had complete RB1 loss with many biopsies (>60%) having a smaller proportion of cancer cells with RB1 loss (<20% cells with RB1 loss), although heterogeneous loss of RB1 in mCRPC was also confirmed (**Figure 4A**). Interestingly, there were several cases with independent complete or heterogeneous loss of one protein but not the other with RNASEH2B loss being surprisingly commoner than RB1 loss (**Figures 4A-B** with exemplar micrographs in **Figure 4C**), and only 1 mCRPC biopsy had co-loss of both proteins. Overall, these results indicate that the RB1 and RNASEH2B proteins are frequently independently lost at a cellular level, with co-loss in the same cell being surprisingly less common; this would be in keeping with the hypothesis that stochastic but independent second allele loss occurs following shared heterozygous deletion of the chromosome 13 locus. This is supported by a general trend of positive correlation when investigating genes between RB1 and RNASEH2B using snRNAseq and bulk RNAseq from the SU2C cohort, in the absence of strong clustering amongst neighboring genes (Supplementary Figure 4F-G).

RNASEH2B loss is not an independent prognostic factor and does not associate with known signatures of DNA damage

In keeping with this discordant loss of expression of RNASEH2B and RB1, there was no evidence for a significant association between median RNASEH2B expression and established prognostic variables (**Supplementary Figure S5A, B**). There was also no evidence for a significant overall difference in median RNASEH2B protein expression based on previous ARSI exposure (abiraterone or enzalutamide), or in relation to the time interval between CRPC diagnosis and CRPC biopsy (**Supplementary Figure S5C**).

The association between mCRPC RNASEH2B protein expression and OS did not appear to be linear; of note, patients with overall low or high RNASEH2B expression had a worse prognosis (**Supplementary Figure S6A**). Because of the absence of a linear relationship, non-linear modelling was pursued with the univariate accelerated failure time (AFT) modelling revealing worse survival for patients with the highest RNASEH2B expression (**Supplementary Figure S6B**). However, in the multivariable

model, once other prognostic factors were accounted for, minimal association between RNASEH2B expression and survival was observed (**Supplementary Figures S6C-D**). RNASEH2B protein expression also was not correlated with the presence of other DDR aberrations including *BRCA2*, *PALB2*, *ATM*, *CDK12* or MMR status (**Supplementary Figure S7A**). RNASEH2B IHC loss was also not significantly associated with established signatures of defective DDR, including telomeric allelic imbalance (NtAI) (25), large-scale transition (LST) (26) and homologous recombination defect loss of heterozygosity (HRD-LOH) scores (27), neither in the overall population or when excluding the impact of other DDR aberrations (**Supplementary Figure S7B**). These scores, which are increasingly used as a candidate predictive biomarker of PARPi response in other cancer types, would therefore not identify RNASEH2B-lost mCRPC.

PARPi treatment impacts clonal selection of RNASEH2B-negative cells

Although preclinical data demonstrated a synthetic lethal relationship between RNASEH2B and PARPi, to date, evidence that this might operate in the clinic is lacking. To evaluate this, we assessed changes in RNASEH2B subclones following PARPi (olaparib) treatment in pre-treatment and on-treatment samples from the TOPARP-A and TOPARP-B trials. Only patients without a *BRCA1/2* gene alteration were evaluated. The percentage of RNASEH2B-negative cells substantially decreased following PARPi treatment in most patients (13/18 patients) consistent with these cellular subclones being cleared by PARPi treatment (**Figure 5A**). We also observed decreasing CellSearch CTC counts on treatment in 6 of these patients, with three of these patients also having a relatively long rPFS despite the absence of *BRCA* gene loss (22 months in a patient with *FANCI* alteration; 13 months in a patient with *ATM* alteration; 8 months in a patient with *CDK12* alteration). Exemplar micrographs of the three patients with the largest changes in percentage of RNASEH2B-negative cells are depicted in **Figure 5B**. Together, these results suggest that RNASEH2B-negative tumor subclones are eradicated by PARPi.

Discussion

RNASEH2B loss has been reported to be synthetic lethal with PARPi in multiple broad genetic perturbation screens (11–13). The current study characterized the landscape of RNASEH2B loss of protein expression in mCRPC. We demonstrate that the RNASEH2B protein is often lost heterogeneously and to varying extents in mCRPC subclones. Complete homogeneous RNASEH2B protein loss by IHC was uncommon and only detected in 8.8% of mCRPC biopsies, consistent with previously reported genomic data (12). Heterogeneous RNASEH2B loss was common with RNASEH2B lost in >50% of cells in 44% of mCRPC biopsies (13). This loss was most common in bone biopsies and although this may have been partly attributable to bone decalcification, the presence of stromal RNASEH2B expression in the presence of tumor loss and similar RNAish data suggested this was not artefactual.

The current study builds on previous findings reporting on RB1 protein loss in CRPC, with this being usually heterogeneous (2, 28) and with shallow genomic loss being much more common than deep loss (29). We previously reported a comprehensive assessment of RB1 loss in matched HSPC/CRPC biopsies by whole genome sequencing (WGS), FISH and IHC, and reported that RB1 loss increased at mCRPC, where 56% of patients had at least shallow RB1 deletion (22), which is in accordance with the IHC data presented in the current study. Surprisingly, despite RB1 and RNASEH2B correlating at a transcriptomic level, loss of RNASEH2B and RB1 protein expression by IHC was discordant at a cellular level. We hypothesize this may be explained by mono-allelic loss of RNASEH2B and RB1 occurring in the same cell, with the second hit occurring stochastically and less likely to occur in the same cell. Our finding that complete loss of both RB1 and RNASEH2B by IHC is uncommon is also in accordance with this hypothesis. The occurrence of a second hit is also supported by data from mCRPC biopsy genomics, where shallow loss of both is far more prevalent than deep loss of both. If RNASEH2B and RB1 loss of expression usually does not occur in the same cell, this may have clinical relevance given the recent observation that RB1 loss can limit PARPi sensitivity generated by RNASEH2B loss, perhaps through E2F1-mediated upregulation of homologous recombination repair (HRR) genes (13).

The extent of RNASEH2B loss required to sensitize to PARPi remains unknown, with studies primarily demonstrating sensitivity in CRISPR knockouts with complete loss of RNASEH2 function (11–13). One study reported double strand breaks (DSB), impaired non-homologous end joining (NHEJ) and increased apoptotic cell death on small hairpin RNA depletion of both RNASEH2A and RNASEH2B in cell lines (30) suggesting that incomplete RNASEH2 loss can impact PARPi sensitivity, with at least one study in chronic lymphatic leukemia (CLL) models suggesting that monoallelic loss may sensitize to PARPi (11). Within mCRPC patients treated with the PARPi olaparib in the TOPARP trials, we show herein that there are clonal dynamics within the RNASEH2B cell population. We report that RNASEH2B-negative subclones by IHC are cleared during PARPi treatment in most *BRCA*-wildtype patients, with this associating with evidence of clinical benefit in some subjects. The degree of benefit imparted is likely dependent on the proportion of tumor impacted by RNASEH2B loss, as well as the molecular makeup of the tumor subclones that are not being cleared. This is supported by the observation that circulating tumor cell (CTC) counts decreased in subjects whose tumors had RNASEH2B loss, without any evidence of radiological benefit. These data suggest that clearance of RNASEH2B-loss clones may, at least in part, be responsible for the observed improved progression-free survival benefit with PARPi in some patients described as not having homologous recombination defects in the PROPEL and TALAPRO-2 trials (9, 10). Importantly, we show that these patients cannot be identified using established DDR signatures and would thus be missed by these assays. Further studies are urgently required to validate these findings and extend the utility of PARPi beyond mCRPC with DDR defects, although this will not be easily feasible utilizing ctDNA studies and may require other biomarker analyses such as circulating tumor cell immunocytochemistry (31).

In summary, the data presented herein demonstrate that RNASEH2B loss of expression displays inter-patient and intra-patient heterogeneity. At a single cell level, RNASEH2B loss often occurs in the absence of RB1 loss, with RNASEH2B subclone loss being cleared by PARPi as previously indicated by multiple genomic screens. These data indicate that prospective studies of RNASEH2B loss need to be incorporated into PARPi predictive assays.

Materials and methods

Sex as a biological variable

Sex was not considered as a variable given the disease etiology.

Patient and tissue samples

Tissues from multiple cohorts were used for the analyses (***Supplementary Figure 1***). Main tissue analyses investigating RNASEH2B and RB1 immunohistochemistry (IHC) were performed with data from one previously reported cohort (immune biomarker (IB) cohort (32), and one not previously reported cohort of mCRPC patients treated at the Royal Marsden Hospital (RMH), the RNASEH2B cohort. Eligible patients were required to have sufficient formalin-fixed, paraffin-embedded (FFPE) CRPC biopsy tissue from a progressing metastatic site. Tissues from the IB cohort were used for whole-exome sequencing (WES), targeted next-generation sequencing (NGS) and RNA sequencing (RNAseq). Patient-matched hormone-sensitive prostate cancer (HSPC) and CRPC biopsies for RNASEH2B IHC came from both the IB and the RNASEH2B cohort. Clinical and demographic data were retrospectively collected from electronic patient records.

For the correlative RNASEH2B and RB1 analyses, data from whole mCRPC biopsies with available whole-exome sequencing (WES) from the IB cohort were analyzed to demonstrate copy number alterations (CNA) as detailed before (32) at the locus of interest on chromosome 13. Chromosome 13 was also analyzed from low-pass whole genome sequencing (lpWGS) on cell free DNA (cfDNA) isolated from plasma samples from CRPC patients treated within three previously reported clinical trials, FIRSTANA (33), PROSELICA (34) and CARD (35), using methods previously published (36). Shallow deletions were defined as a lpWGS log₂ratio between -0.15 and -1; deep deletions were defined as a log₂ratio <-1. RNA sequencing and CNA data generated from the previously reported SU2C/PCF and RMH cohorts were analyzed as published before (22) to evaluate mRNA expression and CNA of *RNASEH2B* and *RB1*. For WES of bulk whole tumor biopsies, deep loss was defined as a CNA estimation equal to -2, and shallow loss or the cases with a CNA estimation equal to -1. For single-nucleus RNA sequencing (snRNASeq), single nuclei were acquired from six frozen mCRPC biopsies (4 lymph node, 2 liver metastases). Tissues for snRNAseq came from

patients providing written informed consent as detailed above (reference 04/Q0801/60).

Tissues from patients participating in TOPARP-A or TOPARP-B (3, 4) were investigated for RNASEH2B RNA in situ hybridization (RNAish) and correlative analyses regarding the clearance of RNASEH2B sub-clones during treatment with olaparib.

Single nucleus RNA sequencing

Tumor biopsies were frozen in optimal cutting temperature compound (OCT) immediately after samples were acquired under ultrasound guidance. Single nuclei were obtained using a modified version of previously described methods (37). Briefly, after dissolving the OCT in cold 1xPBS, tumors were dissociated by chopping the tissue for less than 5 minutes in cold TST lysis buffer (146 mM NaCl, 10 mM Tris-HCl pH 7.5, 1 mM Ca₂Cl₂, 21 mM MgCl₂, 0.05% Tween-20, 0.2 U/μl RNase inhibitor). Dissociated nuclei were first passed through a 70 μM filter and then a 40 μM filter, followed by centrifugation at 500g for 5 min at 4°C. Nuclei pellet was washed with NSB solution (1% BSA/PBS, 0.2 U/μl RNase inhibitor) and then centrifuged at 500g for 5 min at 4°C. Nuclei pellet was resuspended in NSB solution.

snRNASeq was performed using the 10x Genomics (Pleasanton, CA) Chromium Single Cell 5' Library & Gel Bead Kit at the Columbia University Human Immune Monitoring Core (HIMC). Manufacturers' protocols were followed for the preparation of gene expression libraries and the subsequent sequencing on the Illumina (San Diego, CA) NovaSeq 6000 Sequencing System. The sequenced reads were processed by *Cellranger count* (v7.0.0) for cell calling using the default parameters and supplying an indexed hg38 genome as a reference, generated with the *Cellranger mkref* command.

A total of 73,692 nuclei were sequenced and 56,789 high-quality nuclei were obtained after filtering outliers, using the *Scuttle* (v1.4.0) *quickPerCellQC* function, that removed cells possessing library size, feature counts and mitochondrial RNA content that lay 3 absolute deviations from the median. The filtered data was processed with *Seurat*

(v4.3.0) and underwent normalization, scaling, clustering and dimensional reduction before cell type assignment with *SingleR* (v1.8.1) using the *Blueprint ENCODE* reference dataset from the *CellDex* (v1.4.0) package.

Antibody validation and immunohistochemistry

We commissioned an antibody against RNASEH2B from RevMab Biosciences (Burlingame, CA, USA) in a collaborative effort (clone RM433 #31-1321-00). Antibodies against RNASEH2B and RB1 were validated for specificity by western blot, comparing detection of protein in whole cell lysates treated with non-targeting control siRNA or ON-TARGETplus pooled siRNA against the target protein (**Supplementary Table 2**)³⁸. IHC for RNASEH2B was performed using rabbit anti-RNASEH2B antibody (RevMab; controls and conditions are outlined in **Supplementary Table 3**). Sections were counterstained with haematoxylin. Cytoplasmic and nuclear quantification for each sample was determined by a pathologist (BG) blinded to clinical/molecular data using H scores ($[\% \text{ negative staining} \times 0] + [\% \text{ weak staining} \times 1] + [\% \text{ moderate staining} \times 2] + [\% \text{ strong staining} \times 3]$), to determine the overall percentage of positivity across the entire stained samples, yielding a range from 0 to 300. The heterogeneity in RNASEH2B expression was quantified with the Shannon Diversity Index (SDI).

An antibody titration (1:400, 1:200, 1:50) was performed on representative biopsies to validate results. To explore the impact of decalcification on the RNASEH2B staining in bone marrow, an EDTA decalcification protocol was applied to 22Rv1 xenografts prior to RNASEH2B staining. Xenografts were incubated with EDTA solution (decalcifying agent) for 48 hours at 37°C after fixation with neutral buffered formalin (NBF).

Due to the EnVision system used for the main paper analyses being discontinued at the time the TOPARP IHC analyses were done, RNASEH2B IHC for the TOPARP-A/B cohorts was done using a re-optimized assay with Bond Polymer Refine system (Leica Biosystems). The same anti-RNASEH2B monoclonal antibody was used (RevMab Biosciences). Briefly, antigen retrieval was performed for 30 minutes with Bond ER1 solution, anti-RNASEH2B antibody (1:250 dilution) incubated with tissue for 30 minutes and the reaction visualized using Bond Polymer Refine system (Leica Biosystems). Pancreas tissue was used as a positive control. Cell pellets from HeLa

cells treated with control and RNASEH2B siRNA were used to confirm specificity of the antibody for RNASEH2B. Rabbit IgGs were used as negative control.

IHC for RB1 was performed using a ²³mouse anti-RB1 antibody (Cell Signaling Technologies, clone 4H1, #9309; controls and conditions outlined in **Supplementary Table S3**). Sections were counterstained with haematoxylin. Nuclear quantification for each sample was determined by a pathologist (BG) using H scores, as detailed above.

RNA In Situ Hybridisation (RNAish)

RNAish detection was performed on 3µm sections derived from FFPE blocks, with probes for RNASEH2B and PPIB (housekeeping gene for internal control of mRNA quality) on a BOND RX platform (Leica Biosystems) according to manufacturer's protocol (**Supplementary Table S4**).

Slide digitalization and artificial intelligence (AI)-assisted analysis

Stained slides were scanned at high resolution using an Olympus Digital Slide Scanner (Slideview VS200) and analyzed using HALO software (Indica Labs). A supervised machine learning algorithm was trained to differentiate prostate cancer cells from stroma. The algorithm was optimized to provide optical density (OD) data for the intensity of nuclear staining in tumor and stroma for RNASEH2B and RB1. A threshold was defined to label cells as positive (strong/moderate/weak) or negative for each protein, producing the percentage of positive and negative cells in each sample and a HALO-generated H score. HALO and visual analyses correlated well, HALO being more accurate for RB1, as background staining was incorporated into the algorithm. HALO-generated H Score was therefore used for analyses, along with OD, and loss was defined as a HALO-generated H score of less than 15 after careful comparison between negative patient samples and HALO scores by a trained pathologist (BG). To account for weaker RNASEH2B staining on HSPC biopsies, tumor cell OD was normalized to stromal OD for paired biopsies.

For RNAish, slides were scanned as above (40x magnification) and analyzed using the RNAish analysis HALO module. Areas with PPIB expression less than 4 spots/cell were excluded and a threshold for positive and negative cells was defined.

Western blotting

Western blots were performed for antibody validation that were subsequently used for IHC (antibody details listed in **Supplementary Table S3**). Cells were lysed in RIPA buffer supplemented with PhosStop and protease inhibitors (one tablet/10ml RIPA). Lysates were collected with a cell scraper and kept on ice for 30 minutes, followed by sonication (15 seconds) and centrifugation (15 minutes at 4°C). Protein concentration was measured by BCA protein assay kit (Thermo Fisher Scientific). Protein extracts (25µg) were separated on 4-12% NuPAGE® Bis-Tris gel (Invitrogen) by electrophoresis and transferred onto Immobilon-PTM PVDF membranes (0.45 µm, Millipore). Membranes were incubated with red ponceau and blocked in blocking buffer (5x milk TBST/5X BSA TBST) for 1 hour, then incubated in primary antibody overnight at 4°C. Membranes underwent three 5-minute washes in TBS-T before incubating in secondary antibody for 1 hour at room temperature. Three further TBS-T washes were performed before chemiluminescence was detected using Clarity ECL Western blot detection substrate and visualized on the Chemidoc™ Touch imaging system (Bio-Rad).

Defining DNA damage repair gene aberrations and DDR signatures

Targeted next-generation sequencing (NGS) was performed using DNA extracted from CRPC biopsies and germline DNA, according to published protocols (3, 38). Results were used to classify patients according to underlying DDR aberrations. Homologous recombination deficiency (HRD) scores (LST, HRD-related loss of heterozygosity (HRD-LOH), and Number of telomeric Allelic Imbalances (NtAI)) were calculated with HRDetect (39) using ASCAT (40) output from exome sequencing analysis and correlated with RNASEH2B protein expression.

Statistical analyses

Spearman's rank-order coefficient was used to assess correlation. Differences in RNASEH2B expression across biopsy sites were evaluated with the Kruskal-Wallis test. OS from CRPC biopsy was defined from the date of mCRPC biopsy until the time of death, with patients still alive censored at date of last follow-up/contact (data freeze 19th July 2022). RNASEH2B OD was used as a continuous variable to represent RNASEH2B expression. A Weibull distribution was assumed for OS to fit an

accelerated failure time (AFT) model studying the association between OS and log-transformed RNASEH2B OD assuming a linear relationship. As data was obtained from two separate patient cohorts, the model was adjusted for cohort. Restricted cubic splines with three knots were next used to allow modelling non-linear relationships that account for shorter OS at the extremes of the log-transformed RNASEH2B OD scale. Linear and non-linear models were initially run as univariate models. As the timing of the mCRPC biopsy was variable, reduced models adjusting for time from CRPC diagnosis to date of mCRPC biopsy and the patient cohort were run, followed by fully saturated multivariable models adjusting for known prognostic factors. Chi-squared test statistics for the multivariable analyses are presented. For the TOPARP analyses, response was defined in accordance with the primary analysis (3) as either: according to RECIST 1.1; a reduction in PSA of at least 50%, or a conversion in CellSearch circulating tumor cell (CTC) count (from $\geq 5/7.5$ mL of blood to < 5). PSA and CTC changes were required to be confirmed at least four weeks later. Figures and graphs were generated using R v4.2.2.

Study approval

Analyses done in the IB, RNASEH2B and RMH internal cohort were done on samples from patients who provided written informed consent for institutional protocols approved through the RMH ethics review committee (reference 04/Q0801/60). Patients in the TOPARP studies provided written informed consent for institutional protocols approved through the London Surrey Borders ethics committee (REC reference 11/LO/2019).

Data availability

All data has been made available using the supporting data values file as a part of the Supplementary Data. RMH and SU2C-PCF mCRPC cohort RNAseq and WES has been previously made available (2). Further data access requests can be submitted to the corresponding author.

Authors Disclosures

MDF has received grants fees from “Fundación Cris contra el Cáncer”, travel fees from Astellas, AstraZeneca, Pfizer, Pierre Fabre, Roche, Bristol Meiers Squibb, Novartis, MSD, Janssen, MERK, Ipsen and Bayer Pharma, and speakers’ bureau from Janssen, Pierre Fabre and Roche. All outside the submitted work.

CJL receives and/or has received research funding from: AstraZeneca, Merck KGaA, Artios. Received consultancy, SAB membership or honoraria payments from: Syncona, Sun Pharma, Gerson Lehrman Group, Merck KGaA, Vertex, AstraZeneca, Tango, 3rd Rock, Ono Pharma, Artios, Abingworth, Tesselate, Dark Blue Therapeutics, Pontifax, Astex, Neophore, Glaxo Smith Kline. Has stock in: Tango, Ovibio, Hysplex, Tesselate. CJL is also a named inventor on patents describing the use of DNA repair inhibitors and stands to gain from their development and use as part of the ICR “Rewards to Inventors” scheme and also reports benefits from this scheme associated with patents for PARP inhibitors paid into CJL’s personal account and research accounts at the Institute of Cancer Research.

JM has served as an advisor for AstraZeneca, Amunix/Sanofi, Daichii Sankyo, Janssen, MSD; Pfizer, and Roche; is a scientific board member for Nuage Therapeutics; is involved in several investigator-initiated and company-sponsored clinical trials, including some combining PARP inhibitors with AR inhibitors in different clinical settings; has participated in speaker bureaus for AstraZeneca, MSD, Pfizer, Illumina, and Guardant; and is the Principal Investigator of research projects funded by institutional grants from AstraZeneca and Pfizer.

AS is an employee of the ICR, which has a commercial interest in abiraterone, PARP inhibition in DNA repair defective cancers, and PI3K/AKT pathway inhibitors (no personal income). A.S has received travel support from Sanofi, Roche-Genentech and Nurix, and speaker honoraria from Astellas Pharma and Merck Sharp & Dohme. He has served as an advisor to DE Shaw Research and CHARM Therapeutics. A.S has been the CI/PI of industry sponsored clinical trials.

JDB has served on advisory boards and received fees from many companies including Amgen, Astra Zeneca, Astellas, Bayer, Bioexcel Therapeutics, Boehringer Ingelheim,

Cellcentric, Daiichi, Eisai, Genentech/Roche, Genmab, GSK, Harpoon, ImCheck Therapeutics, Janssen, Merck Serono, Merck Sharp & Dohme, Menarini/Silicon Biosystems, Orion, Pfizer, Qiagen, Sanofi Aventis, Sierra Oncology, Taiho, Terumo, Vertex Pharmaceuticals. He is an employee of The ICR, which have received funding or other support for his research work from AZ, Astellas, Bayer, Cellcentric, Daiichi, Genentech, Genmab, GSK, Janssen, Merck Serono, MSD, Menarini/Silicon Biosystems, Orion, Sanofi Aventis, Sierra Oncology, Taiho, Pfizer, Vertex, and which has a commercial interest in abiraterone, PARP inhibition in DNA repair defective cancers and PI3K/AKT pathway inhibitors (no personal income). JDB was named as an inventor, with no financial interest for patent 8,822,438, submitted by Janssen that covers the use of abiraterone acetate with corticosteroids. He has been the CI/PI of many industry sponsored clinical trials. JDB is a National Institute for Health Research (NIHR) Senior Investigator. The views expressed in this article are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health.

The remaining authors declare no conflicts of interest.

Authors contributions

J. Carmichael: Conceptualization, data curation, formal analysis, validation, investigation, visualization, methodology, project administration, funding acquisition, writing and editing. **I. Figueiredo:** Conceptualization, data curation, validation, investigation, visualization, methodology, writing and editing. **B. Gurel:** Conceptualization, data curation, formal analysis, investigation, visualization, methodology, writing and editing. **N. Beije:** Data curation, investigation, writing and editing. **W. Yuan:** Software, investigation, formal analysis, methodology, data curation, supervision, writing and editing. **J. Rekowski:** Software, formal analysis, investigation, visualization, methodology, writing and editing. **G. Seed:** Data curation, software, formal analysis, visualization. **S. Carreira:** Data curation, Investigation, software. **C. Bertan:** Data curation, Investigation, software. **M.D. Fenor de la Maza:** Data curation. **K. Chandran:** Data curation. **A. Neeb:** Validation. **J. Welti:** Validation. **L. Gallagher:** Software, formal analysis, visualization. **D. Bogdan:** Software, visualization. **M. Crespo:** Data curation. **R. Riisnaes:** Data curation. **A. Ferreira:** Data curation. **S. Miranda:** Data curation. **J. Lu:** data curation. **M. Shen:** data curation. **E. Hall:** data curation. **N. Porta:** data curation, formal analysis. **D. Westaby:** Data curation. **C. Guo:** Data curation. **R. Grochot:** Data curation. **C. Lord:** formal analysis, writing and editing. **J. Mateo:** investigation, writing and editing. **A. Sharp:** Supervision, writing and editing. **J. de Bono:** Conceptualization, resources, supervision, funding acquisition, project administration, writing and editing.

Acknowledgements

The authors gratefully acknowledge the patients and the families of patients who contributed to this study. TOPARP is an investigator-initiated trial; we are grateful for the support and funding from AstraZeneca, and for the study grants from Cancer Research UK (CRUK/11/029; C12540/A12829; C12540/A13230; C12540/A20447).

This work was supported by the Medical Research Council (Clinical Research Training Fellowship to J.C MR/T029293/1), the Wellcome Trust (Clinical Research Career Development Fellowship to A.S. and Clinical Research Training Fellowship to C.G.) and Cancer Research UK (Clinical Research Training Fellowship to D.W.), the Department of Defense (Early Investigator Research Award to J.L. W81XWH-22-1-0078 and Research Program Award to M.S. W81XWH2110077) and National Institute of Health (Award to M.S. P01 CA265768). We also acknowledge research funding for

RNASEH2B in advanced prostate cancer

this work from Prostate Cancer UK, the Movember Foundation through the London Movember Centre of Excellence (CEO13_2-002), the Prostate Cancer Foundation, Experimental Cancer Medicine Centre grant funding from Cancer Research UK and the Department of Health, and Biomedical Research Centre funding to the Royal Marsden.

References

1. International WCRF. Prostate cancer statistics World Cancer Research Fund International 2023 [updated 23 March 2022 13/04/2023] [Internet]. Available from: <https://www.wcrf.org/cancer-trends/prostate-cancer-statistics/>.
2. Robinson D, et al. Integrative clinical genomics of advanced prostate cancer. *Cell*. 2015;161(5):1215–1228.
3. Mateo J, et al. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. *N Engl J Med*. 2015;373(18):1697–708.
4. Mateo J, et al. Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. *Lancet Oncol*. 2020;21(1):162–174.
5. de Bono J, et al. Olaparib for Metastatic Castration-Resistant Prostate Cancer. *N Engl J Med*. 2020;382(22):2091–2102.
6. Hussain M, et al. Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. *N Engl J Med*. 2020;383(24):2345–2357.
7. Carreira S, et al. Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial. *Cancer Discov*. 2021;11(11):2812–2827.
8. Perez-Lopez R, et al. High frequency of radiological differential responses with poly(ADP-Ribose) polymerase (PARP) inhibitor therapy. *Oncotarget*. 2017;8(61):104430–104443.
9. Clarke NW, et al. Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer. *NEJM Evidence*. 2022;1(9). <https://doi.org/10.1056/EVIDoa2200043>.
10. Agarwal N, et al. Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial. *The Lancet*. 2023;402(10398):291–303.
11. Zimmermann M, et al. CRISPR screens identify genomic ribonucleotides as a source of PARP-trapping lesions. *Nature*. 2018;559(7713):285–289.
12. Wang C, et al. Genome-wide CRISPR screens reveal synthetic lethality of RNASEH2 deficiency and ATR inhibition. *Oncogene*. 2019;38(14):2451–2463.
13. Miao C, et al. *RB1* loss overrides PARP inhibitor sensitivity driven by *RNASEH2B* loss in prostate cancer. *Sci Adv*. 2022;8(7). <https://doi.org/10.1126/sciadv.abl9794>.
14. Chon H, et al. Contributions of the two accessory subunits, RNASEH2B and RNASEH2C, to the activity and properties of the human RNase H2 complex. *Nucleic Acids Res*. 2009;37(1):96–110.
15. Skourti-Stathaki K, Proudfoot NJ. A double-edged sword: R loops as threats to genome integrity and powerful regulators of gene expression. *Genes Dev*. 2014;28(13):1384–96.
16. Cristini A, et al. RNase H2, mutated in Aicardi-Goutières syndrome, resolves co-transcriptional R-loops to prevent DNA breaks and inflammation. *Nat Commun*. 2022;13(1):2961.
17. Förstemann K, Lingner J. Telomerase limits the extent of base pairing between template RNA and telomeric DNA. *EMBO Rep*. 2005;6(4):361–6.
18. Pryor JM, et al. Ribonucleotide incorporation enables repair of chromosome breaks by nonhomologous end joining. *Science*. 2018;361(6407):1126–1129.
19. Li Y, Breaker RR. Kinetics of RNA Degradation by Specific Base Catalysis of Transesterification Involving the 2'-Hydroxyl Group. *J Am Chem Soc*. 1999;121(23):5364–5372.
20. Reijns MAM, et al. Enzymatic removal of ribonucleotides from DNA is essential for mammalian genome integrity and development. *Cell*. 2012;149(5):1008–22.

21. Kluth M, et al. 13q deletion is linked to an adverse phenotype and poor prognosis in prostate cancer. *Genes Chromosomes Cancer*. 2018;57(10):504–512.
22. Nava Rodrigues D, et al. RB1 Heterogeneity in Advanced Metastatic Castration-Resistant Prostate Cancer. *Clin Cancer Res*. 2019;25(2):687–697.
23. Tan H-L, et al. Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma. *Clin Cancer Res*. 2014;20(4):890–903.
24. Brough R, et al. Identification of highly penetrant Rb-related synthetic lethal interactions in triple negative breast cancer. *Oncogene*. 2018;37(43):5701–5718.
25. Birkbak NJ, et al. Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents. *Cancer Discov*. 2012;2(4):366–375.
26. Popova T, et al. Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation. *Cancer Res*. 2012;72(21):5454–62.
27. Abkevich V, et al. Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer. *Br J Cancer*. 2012;107(10):1776–82.
28. Williams JL, Greer PA, Squire JA. Recurrent copy number alterations in prostate cancer: an in silico meta-analysis of publicly available genomic data. *Cancer Genet*. 2014;207(10–12):474–88.
29. Camacho N, et al. Appraising the relevance of DNA copy number loss and gain in prostate cancer using whole genome DNA sequence data. *PLoS Genet*. 2017;13(9):e1007001.
30. Ghosh D, Kumari S, Raghavan SC. Depletion of RNASEH2 Activity Leads to Accumulation of DNA Double-strand Breaks and Reduced Cellular Survivability in T Cell Leukemia. *J Mol Biol*. 2022;434(12):167617.
31. de Bono JS, et al. Potential applications for circulating tumor cells expressing the insulin-like growth factor-I receptor. *Clin Cancer Res*. 2007;13(12):3611–6.
32. Fenor de la Maza MD, et al. Immune Biomarkers in Metastatic Castration-resistant Prostate Cancer. *Eur Urol Oncol*. 2022;5(6):659–667.
33. Oudard S, et al. Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA. *J Clin Oncol*. 2017;35(28):3189–3197.
34. Eisenberger M, et al. Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m²) and the Currently Approved Dose (25 mg/m²) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer-PROSELICA. *J Clin Oncol*. 2017;35(28):3198–3206.
35. de Wit R, et al. Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer. *N Engl J Med*. 2019;381(26):2506–2518.
36. Sumanasuriya S, et al. Elucidating Prostate Cancer Behaviour During Treatment via Low-pass Whole-genome Sequencing of Circulating Tumour DNA. *Eur Urol*. 2021;80(2):243–253.
37. Drokhlyansky E, et al. The Human and Mouse Enteric Nervous System at Single-Cell Resolution. *Cell*. 2020;182(6):1606-1622.e23.
38. Goodall J, et al. Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition. *Cancer Discov*. 2017;7(9):1006–1017.
39. Davies H, et al. HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures. *Nat Med*. 2017;23(4):517–525.
40. Van Loo P, et al. Allele-specific copy number analysis of tumors. *Proc Natl Acad Sci U S A*. 2010;107(39):16910–5.




Figure 1: RNASEH2B and RB1 gene expression in CRPC. (A) *RNASEH2B*, *RB1* and *BRCA2* are located in close proximity on chromosome 13. (B) *RNASEH2B* and *RB1* deletions, most frequently shallow, were commonly observed in whole mCRPC biopsies from a RMH whole exome cohort (n=93) and lpWGS of plasma DNA from 267 patients treated in three clinical trials (FIRSTANA, PROSELICA, CARD). (C) Scatter plot of *RNASEH2B* and *RB1* mRNA expression (quantile normalized) in the SU2C/PCF (blue) and RMH (red) CRPC cohorts. r and p values were calculated using Spearman correlation. (D) Association between copy number and RNA expression of *RB1* and *RNASEH2B* in the SU2C/PCF (n=106) and RMH cohorts (n=87), suggesting that especially for the latter stage RMH cohort that detectable whole biopsy shallow loss at a DNA level is associated with loss of *RNASEH2B* expression. Horizontal bars denote IQRs and medians. Combined CNA and RNA expression was only present for a subset of the cohorts as depicted in Figure 1C. (E) Single nucleus RNAseq of 6 CRPC patients demonstrating the expression of the *RB1* and *RNASEH2B* gene in a single nucleus. lpWGS= low-pass whole genome sequencing; CNA= copy number alteration; IQR = interquartile range; CRPC= castration resistant prostate cancer




Figure 2: Validation and optimization of a RNASEH2B (RM433) antibody for IHC (A) RNASEH2B antibody specificity confirmed by western blotting of whole-cell lysates from HeLa cells treated with non-targeting control siRNA and pooled RNASEH2B siRNA. (B) IHC was run on HeLa cell pellets being treated with non-targeting control siRNA and pooled RNASEH2B siRNA, as well as HeLa RNASEH2B gene knock-outs and normal human pancreatic tissue. IHC depicted here with x10 magnification and 100 μ m scale bar. (C-E) Scatter plots showing associations between RNASEH2B IHC quantification by visual nuclear H score conducted by blinded pathologist and AI-trained HALO-generated OD, % negative cells and digital nuclear H Score. r and p values were calculated using Spearman correlation (F) Representative micrographs of RNASEH2B detection by IHC. Examples of high, low heterogenous (interspersed and sub-clonal) protein expression are shown. IHC depicted here with x10 magnification and 100 μ m scale band. IHC= Immunohistochemistry; KO= knock-out; PC= prostate cancer; AI= artificial intelligence; OD= optical density.








Figure 3: Landscape of RNASEH2B protein expression by IHC in CRPC and HSPC (A) Graphical representation of RNASEH2B protein expression in 124 CRPC biopsies (HALO generated H-Score, OD and % negative cells) and intra-sample heterogeneity, quantified by Shannon's diversity index, across biopsy sites. **(B)** Box plot of RNASEH2B % loss by biopsy site, with plot to demonstrate the distribution. Horizontal bars denote IQR and medians. Kruskal-Wallis test was performed. **(C)** HALO was used to calculate the % RNASEH2B negative cells by IHC in each sample, depicted as a histogram for all samples, and for non bone marrow samples alone. **(D)** Violin plot of RNASEH2B-negative cells by IHC in paired, same-patient HSPC and CRPC biopsies (n = 34). Dots represent RNASEH2B-negative cells per sample, line represents median for whole group. **(E)** Representative micrographs of RNASEH2B detection by IHC in matched, same-patient HSPC and CRPC biopsies. Examples of complete RNASEH2B loss at HSPC and CRPC (1), and emergence of complete (2) or heterogeneous (3) RNASEH2B loss at CRPC are shown. IHC depicted here with x10 magnification and 100µm scale bar. IQR = interquartile range; CRPC= castration resistant prostate cancer; HSPC= hormone-sensitive prostate cancer; IHC= Immunohistochemistry; OD= Optical density.





Figure 4: Evaluation of RB1 and RNASEH2B protein expression at CRPC by IHC (A) Graphical representation of RB1 and RNASEH2B protein expression in 93 CRPC biopsies (HALO generated H Score, OD and % negative cells) and intra-sample heterogeneity, quantified by Shannon's diversity index, across biopsy sites. Samples are matched, displayed in order of increasing RNASEH2B nuclear H score for both plots. **(B)** Scatter plot showing association between RNASEH2B and RB1 IHC quantification by HALO-generated % negative cells and OD. Scatterplots on the right distribute samples according to biopsy site, in bone-marrow alone and non-bone marrow (soft tissue, liver, lymph node, prostate) samples. r and p values were calculated using Spearman correlation. **(C)** Representative micrographs of RB1 and RNASEH2B detection by IHC in matched, same-patient CRPC biopsies. Examples of concordant RNASEH2B and RB1 expression (1), heterogeneous loss of both RB1 and RNASEH2B (2), RB1 loss alone (3), RB1 loss with heterogeneous RNASEH2B (4) and RNASEH2B loss alone (5) at various biopsy sites are shown. IHC depicted here with $\times 10$ magnification and $100\mu\text{m}$ scale bar. While in a whole biopsy RB1 and RNASEH2B protein loss correlate, with both proteins being commonly heterogeneously lost, surprisingly the data indicate that different cells in a biopsy often lose one protein or the other with only a minority of cells having co-loss of both proteins. IHC = Immunohistochemistry; IQR = interquartile range; CRPC= castration resistant prostate cancer; OD= Optical density

A



B




Figure 5: Changes in RNASEH2B expression in patients treated with PARP inhibitor Olaparib in TOPARP trials. (A) Matched pre-treatment and on-treatment biopsies were compared for RNASEH2B expression in patients without an identified *BRCA* alteration. Pre-treatment percentage of RNASEH2B-negative cells are depicted above the waterfall plots. First waterfall plot depict the absolute change in percentage of RNASEH2B-negative cells (on treatment % minus pre-treatment %). Second waterfall plots depicts the percentage change in CTC number (by CellSearch) from pre-treatment to 12-weeks of treatment. Tiles below depict which DDR alteration was identified in each specific patient. **(B)** Exemplar micrographs of RNASEH2B expression by IHC in the three cases with the largest percentage change in RNASEH2B-negative cells from pre-treatment to on-treatment. IHC depicted here with x10 magnification and 100 μ m scale bar. CTC= circulating tumor cells; IHC= immunohistochemistry.